A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, with patients who received the one-time IV therapy with more than 90% decrease in bleeding events 2 to 3 years after treatment, reports the early clinical trial in the New England Journal of Medicine.

A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, with patients who received the one-time IV therapy with more than 90% decrease in bleeding events 2 to 3 years after treatment, reports the early clinical trial in the New England Journal of Medicine.: https://ift.tt/2SM7gTd Read more... https://ift.tt/2QkELKP